FORTRESS BIOTECH.PRF.A 25
Research FORTRESS BIOTECH.PRF.A 25 (CNB0) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerCNB0
- ExchangeF
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Financial periodQ1 2026
- RevenueUSD 16.04M
- Net incomeUSD 110.37M
- Free cash flowUSD 203.85M
- Gross margin61.2%
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 63.26M | USD 6.82M | -USD 65.78M | 66.9% | n/a | USD 79.38M | USD 74.30M | USD 49.87M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | n/a | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About FORTRESS BIOTECH.PRF.A 25
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne;
Related stock research
Other Healthcare stocks
Frequently asked questions
What does FORTRESS BIOTECH.PRF.A 25 do?
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally.